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1

CASE SERIES
We describe 3 patients (3 eyes) whom received treatment with intravitreal injection with aflibercept for choroidal neovascularization secondary to Serpiginous Choroiditis (SC). To the best of our knowledge, aflibercept has not been described previously for this indication in the medical literature. All patients developed classic types of choroidal neovascularization in one of their eyes and received 2-7 intravitreal injections of aflibercept (EYLEA, Regeneron, Tarrytown, NY, USA) (Table 1) . Follow-up time after the first intravitreal injection ranged between 8-14 months. Horizontal macular spectral domain optical coherence tomography showed regression of choroidal neovascularization in all patients ( Figure 1 ). Multifocal electroretinography showed severely reduced function in the macular area affected by the SC, and preserved function in the uninvolved macula, thus documenting sparing of regional macular function after treatment with aflibercept ( Figure 2 ). Full-field electroretinography demonstrated rod and cone responses within normal limits before and after treatment (Table 1 ). Autofluorescence imaging demonstrated progressive reduction of inflammatory activity, seen as diminishing hyperautofluorescence, at the leading edges of the lesion, for each intravitreal injection of aflibercept ( Fig. 1) .
COMMENT
SC is known to be progressive and carries a guarded prognosis with respect to visual outcome. There is no solid documentation of efficacy of any of the immunosuppressive strategies used in the treatment for this condition.
Due to the low frequency of SC, randomized trials are unlikely to provide answers regarding optimal immunosuppression in SC.
Herein we present 3 cases with SC in whom secondary neovascularization developed and treatment was instituted with general immunosuppression and intravitreal injections of aflibercept. Previous studies have described intravitreal ranibizumab and bevacizumab for this condition, however to the best of our knowledge, intravitreal aflibercept use has not been described previously for SC and its complications (Parodi et al. 2014 , Balaskas et al. 2012 , Song & Roh 2009 ). Among previous studies, the best documented series, using bevacizumab in 7 eyes, demonstrated improved function of at least 5 and 10 ETDRS letters in two eyes, and one eye, respectively, at the 12-month follow-up (Parodi et al. 2014) . Four eyes had stable vision and one eye experienced a two-line decrease (Parodi et al. 2014) .
Median central macular thickness at baseline was 261 μm, decreasing to 196 μm at the 12-month examination (Parodi et al. 2014) . The median number of injections was 1 in 12 months (Parodi et al. 2014) . In our series, choroidal neovascularization regressed in all 3 patients, with a concomitant decrease in central retinal thickness, however 2 out of 3 patients lost vision compared to baseline (Table 1 ).
2 Albeit the pathogenesis of SC remains largely unknown, intravitreal aflibercept may have advantages over ranibizumab or bevazcizumab in the treatment of neovascular complications in SC. Aflibercept binds to circulating vascular endothelial growth factors (VEGFs) and acts like a "VEGF trap". It thereby shows a more broad mechanism of action compared to the former 2 drugs, inhibiting not only vascular endothelial growth factor subtype VEGF -A, but also VEGF-B, as well as placental growth factor (PGF) (Stewart et al. 2012 ). Furthermore, the Fc portion of the human IgG1 immunoglobulin in the recombinant aflibercept protein may also exert favourable immunological effects which may potentially affect the disease course. In keeping with this, we were able to demonstrate areas of remaining macular function by multifocal electroretinography, in the area that was not directly affected by the SC, after treatment with aflibercept.
Limitations of the present study include small sample size, and electrophysiological studies were performed in only 1 patient. Furthermore, the given generalized immunosuppressive medication may also have local effects contributing to the regression of choroidal neovascularization, thus any treatment effects may not be attributed to aflibercept only.
In summary, although there are significant limitations as mentioned above, we present potentially promising data which require further exploration, regarding the role of intravitreal aflibercept in SC affected by secondary choroidal neovascularization. 
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